{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T05:21:03Z","timestamp":1784956863447,"version":"3.55.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,8,26]]},"DOI":"10.7759\/cureus.28421","type":"journal-article","created":{"date-parts":[[2022,8,26]],"date-time":"2022-08-26T08:27:15Z","timestamp":1661502435000},"source":"Crossref","is-referenced-by-count":3,"title":["The Outcome of Hodgkin Lymphoma With Reference to Prognostic Markers"],"prefix":"10.7759","author":[{"given":"Rehana","family":"Ahmed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faryal","family":"Tariq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javeria","family":"Ashfaq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Warkha","family":"Thakur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sidra","family":"Zafar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asma","family":"Danish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Munira","family":"Borhany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1080\/14737140.2021.1918548","article-title":"Immune checkpoint inhibition in classical hodgkin lymphoma","volume":"21","author":"Pezeshki PS","year":"2021","unstructured":"Pezeshki PS, Eskian M, Hamblin MR, Rezaei N. Immune checkpoint inhibition in classical hodgkin lymphoma. Expert Rev Anticancer Ther. 2021, 21:1003-1016. 10.1080\/14737140.2021.1918548","journal-title":"Expert Rev Anticancer Ther"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1080\/08998280.2005.11928096","article-title":"Thomas Hodgkin: medical immortal and uncompromising idealist","volume":"18","author":"Stone MJ","year":"2005","unstructured":"Stone MJ. Thomas Hodgkin: medical immortal and uncompromising idealist. Proc (Bayl Univ Med Cent). 2005, 18:368-375. 10.1080\/08998280.2005.11928096","journal-title":"Proc (Bayl Univ Med Cent)"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2021.2024819","article-title":"Current salvage therapies in Hodgkin lymphoma","volume":"63","author":"Chohan K","year":"2022","unstructured":"Chohan K, Ansell SM. Current salvage therapies in Hodgkin lymphoma. Leuk Lymphoma. 2022, 63:1267-1280. 10.1080\/10428194.2021.2024819","journal-title":"Leuk Lymphoma"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/s0145-2126(01)00126-6","article-title":"Hodgkin's disease in Asians: incidence patterns and risk factors in population-based data","volume":"26","author":"Glaser SL","year":"2002","unstructured":"Glaser SL, Hsu JL. Hodgkin's disease in Asians: incidence patterns and risk factors in population-based data. Leuk Res. 2002, 26:261-269. 10.1016\/s0145-2126(01)00126-6","journal-title":"Leuk Res"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v27.i34.5764","article-title":"Secular decreasing trends in gastric cancer incidence in Taiwan: a population-based cancer registry study","volume":"27","author":"Lin YT","year":"2021","unstructured":"Lin YT, Chiang CJ, Yang YW, Huang SP, You SL. Secular decreasing trends in gastric cancer incidence in Taiwan: a population-based cancer registry study. World J Gastroenterol. 2021, 27:5764-5774. 10.3748\/wjg.v27.i34.5764","journal-title":"World J Gastroenterol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21438","article-title":"Hodgkin lymphoma: a review and update on recent progress","volume":"68","author":"Shanbhag S","year":"2018","unstructured":"Shanbhag S, Ambinder RF. Hodgkin lymphoma: a review and update on recent progress. CA Cancer J Clin. 2018, 68:116-132. 10.3322\/caac.21438","journal-title":"CA Cancer J Clin"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2015.10.022","article-title":"Association of intensity-modulated radiation therapy on overall survival for patients with Hodgkin lymphoma","volume":"118","author":"Parikh RR","year":"2016","unstructured":"Parikh RR, Grossbard ML, Harrison LB, Yahalom J. Association of intensity-modulated radiation therapy on overall survival for patients with Hodgkin lymphoma. Radiother Oncol. 2016, 118:52-59. 10.1016\/j.radonc.2015.10.022","journal-title":"Radiother Oncol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.5911","article-title":"Association of combined modality therapy vs chemotherapy alone with overall survival in early-stage pediatric Hodgkin lymphoma","volume":"5","author":"Jhawar SR","year":"2019","unstructured":"Jhawar SR, Rivera-N\u00fa\u00f1ez Z, Drachtman R, Cole PD, Hoppe BS, Parikh RR. Association of combined modality therapy vs chemotherapy alone with overall survival in early-stage pediatric Hodgkin lymphoma. JAMA Oncol. 2019, 5:689-695. 10.1001\/jamaoncol.2018.5911","journal-title":"JAMA Oncol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13943","article-title":"No survival benefit associated with routine surveillance imaging for Hodgkin lymphoma in first remission: a Danish-Swedish population-based observational study","volume":"173","author":"Jakobsen LH","year":"2016","unstructured":"Jakobsen LH, Hutchings M, de Nully Brown P, et al.. No survival benefit associated with routine surveillance imaging for Hodgkin lymphoma in first remission: a Danish-Swedish population-based observational study. Br J Haematol. 2016, 173:236-244. 10.1111\/bjh.13943","journal-title":"Br J Haematol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199811193392104","article-title":"A prognostic score for advanced Hodgkin's disease. International prognostic factors project on advanced Hodgkin's disease","volume":"339","author":"Hasenclever D","year":"1998","unstructured":"Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. International prognostic factors project on advanced Hodgkin's disease. N Engl J Med. 1998, 339:1506-1514. 10.1056\/NEJM199811193392104","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.73.8369","article-title":"On the role of interim fluorine-18-labeled fluorodeoxyglucose positron emission tomography in early-stage favorable Hodgkin lymphoma","volume":"35","author":"Hindi\u00e9 E","year":"2017","unstructured":"Hindi\u00e9 E, Mesguich C, Zanotti-Fregonara P. On the role of interim fluorine-18-labeled fluorodeoxyglucose positron emission tomography in early-stage favorable Hodgkin lymphoma. J Clin Oncol. 2017, 35:2851-2852. 10.1200\/JCO.2017.73.8369","journal-title":"J Clin Oncol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30784-8","article-title":"PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study","volume":"20","author":"Casasnovas RO","year":"2019","unstructured":"Casasnovas RO, Bouabdallah R, Brice P, et al.. PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study. Lancet Oncol. 2019, 20:202-215. 10.1016\/S1470-2045(18)30784-8","journal-title":"Lancet Oncol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1510093","article-title":"Adapted treatment guided by interim PET-CT scan in advanced Hodgkin's lymphoma","volume":"374","author":"Johnson P","year":"2016","unstructured":"Johnson P, Federico M, Kirkwood A, et al.. Adapted treatment guided by interim PET-CT scan in advanced Hodgkin's lymphoma. N Engl J Med. 2016, 374:2419-2429. 10.1056\/NEJMoa1510093","journal-title":"N Engl J Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1994.12.3.580","article-title":"Dexa-BEAM in patients with Hodgkin's disease refractory to multidrug chemotherapy regimens: a trial of the German Hodgkin's Disease Study Group","volume":"12","author":"Pfreundschuh MG","year":"1994","unstructured":"Pfreundschuh MG, Rueffer U, Lathan B, et al.. Dexa-BEAM in patients with Hodgkin's disease refractory to multidrug chemotherapy regimens: a trial of the German Hodgkin's Disease Study Group. J Clin Oncol. 1994, 12:580-586. 10.1200\/JCO.1994.12.3.580","journal-title":"J Clin Oncol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2015.07.005","article-title":"Hodgkin lymphoma: diagnosis and treatment","volume":"90","author":"Ansell SM","year":"2015","unstructured":"Ansell SM. Hodgkin lymphoma: diagnosis and treatment. Mayo Clin Proc. 2015, 90:1574-1583. 10.1016\/j.mayocp.2015.07.005","journal-title":"Mayo Clin Proc"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2016.05.010","article-title":"Treatment of relapsed and refractory Hodgkin lymphoma","volume":"53","author":"von Tresckow B","year":"2016","unstructured":"von Tresckow B, Moskowitz CH. Treatment of relapsed and refractory Hodgkin lymphoma. Semin Hematol. 2016, 53:180-185. 10.1053\/j.seminhematol.2016.05.010","journal-title":"Semin Hematol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djw249","article-title":"Hodgkin lymphoma: current status and clinical trial recommendations","volume":"109","author":"Diefenbach CS","year":"2017","unstructured":"Diefenbach CS, Connors JM, Friedberg JW, et al.. Hodgkin lymphoma: current status and clinical trial recommendations. J Natl Cancer Inst. 2017, 109:10.1093\/jnci\/djw249","journal-title":"J Natl Cancer Inst"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2016.05.007","article-title":"Hodgkin lymphoma: pathology and biology","volume":"53","author":"Mathas S","year":"2016","unstructured":"Mathas S, Hartmann S, K\u00fcppers R. Hodgkin lymphoma: pathology and biology. Semin Hematol. 2016, 53:139-147. 10.1053\/j.seminhematol.2016.05.007","journal-title":"Semin Hematol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2019.1665666","article-title":"Prognostic factors in pediatric Hodgkin lymphoma: experience from a developing country","volume":"61","author":"Ghafoor T","year":"2020","unstructured":"Ghafoor T. Prognostic factors in pediatric Hodgkin lymphoma: experience from a developing country. Leuk Lymphoma. 2020, 61:344-350. 10.1080\/10428194.2019.1665666","journal-title":"Leuk Lymphoma"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(195709\/10)10:5<1045::aid-cncr2820100527>3.0.co;2-0","article-title":"Epidemiological evidence of the nature of Hodgkin's disease","volume":"10","author":"MacMahon B","year":"1957","unstructured":"MacMahon B. Epidemiological evidence of the nature of Hodgkin's disease. Cancer. 1957, 10:1045-1054. 10.1002\/1097-0142(195709\/10)10:5&lt;1045::aid-cncr2820100527&gt;3.0.co;2-0","journal-title":"Cancer"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2011.08975.x","article-title":"Management of children with high-risk Hodgkin lymphoma","volume":"157","author":"Kelly KM","year":"2012","unstructured":"Kelly KM. Management of children with high-risk Hodgkin lymphoma. Br J Haematol. 2012, 157:3-13. 10.1111\/j.1365-2141.2011.08975.x","journal-title":"Br J Haematol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdf228","article-title":"The International Prognostic Factors Project score for advanced Hodgkin's disease is useful for predicting outcome of autologous hematopoietic stem cell transplantation","volume":"13","author":"Bierman PJ","year":"2002","unstructured":"Bierman PJ, Lynch JC, Bociek RG, Whalen VL, Kessinger A, Vose JM, Armitage JO. The International Prognostic Factors Project score for advanced Hodgkin's disease is useful for predicting outcome of autologous hematopoietic stem cell transplantation. Ann Oncol. 2002, 13:1370-1377. 10.1093\/annonc\/mdf228","journal-title":"Ann Oncol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1055\/s-0040-1701853.","article-title":"Retrospective analysis of baseline prognostic factors on the outcome of pediatric Hodgkin lymphoma in a tertiary cancer centre","volume":"232","author":"Sindhu II","year":"2020","unstructured":"Sindhu II. Retrospective analysis of baseline prognostic factors on the outcome of pediatric Hodgkin lymphoma in a tertiary cancer centre. Klin Padiatr. 2020, 232:93. 10.1055\/s-0040-1701853.","journal-title":"Klin Padiatr"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.4084\/MJHID.2014.053","article-title":"Prognostic factors in Hodgkin lymphoma","volume":"6","author":"Cuccaro A","year":"2014","unstructured":"Cuccaro A, Bartolomei F, Cupelli E, Galli E, Giachelia M, Hohaus S. Prognostic factors in Hodgkin lymphoma. Mediterr J Hematol Infect Dis. 2014, 6:e2014053. 10.4084\/MJHID.2014.053","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000847172.03644.33","article-title":"A retrospective analysis on old and emerging prognostic factors in classical Hodgkin's lymphoma in the PET-guided era.","volume":"6","author":"Cellini A","year":"2022","unstructured":"Cellini A, Cavarretta CA, Pravato S, et.al.. A retrospective analysis on old and emerging prognostic factors in classical Hodgkin's lymphoma in the PET-guided era.. HemaSphere. 2022, 6:966-967. 10.1097\/01.HS9.0000847172.03644.33","journal-title":"HemaSphere"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2035","article-title":"Tumour burden at diagnosis as the main clinical predictor of cell resistance in patients with early stage, favourable Hodgkin lymphoma treated with VBM chemotherapy plus radiotherapy","volume":"31","author":"Gobbi PG","year":"2013","unstructured":"Gobbi PG, Bergonzi M, Bassi E, Merli F, Coriani C, Federico M. Tumour burden at diagnosis as the main clinical predictor of cell resistance in patients with early stage, favourable Hodgkin lymphoma treated with VBM chemotherapy plus radiotherapy. Hematol Oncol. 2013, 31:151-155. 10.1002\/hon.2035","journal-title":"Hematol Oncol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1080\/14737140.2016.1182428","article-title":"The evolving role of radiation therapy in pediatric Hodgkin's disease","volume":"16","author":"Fredman E","year":"2016","unstructured":"Fredman E, Mansur DB, Russo S. The evolving role of radiation therapy in pediatric Hodgkin's disease. Expert Rev Anticancer Ther. 2016, 16:605-613. 10.1080\/14737140.2016.1182428","journal-title":"Expert Rev Anticancer Ther"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1992.10.2.210","article-title":"Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: the low probability for cure","volume":"10","author":"Longo DL","year":"1992","unstructured":"Longo DL, Duffey PL, Young RC, et al.. Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: the low probability for cure. J Clin Oncol. 1992, 10:210-218. 10.1200\/JCO.1992.10.2.210","journal-title":"J Clin Oncol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/s1658-3876(09)50038-6","article-title":"Clinical characteristics and outcome of pediatric patients with stage IV Hodgkin lymphoma","volume":"2","author":"Belgaumi A","year":"2009","unstructured":"Belgaumi A, Al-Kofide AA, Khafaga Y, Joseph N, Jamil-Malik R, Siddiqui KS, Sabbah RS. Clinical characteristics and outcome of pediatric patients with stage IV Hodgkin lymphoma. Hematol Oncol Stem Cell Ther. 2009, 2:278-284. 10.1016\/s1658-3876(09)50038-6","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.26278","article-title":"Childhood Hodgkin International Prognostic Score (CHIPS) predicts event-free survival in Hodgkin lymphoma: a report from the Children's Oncology Group","volume":"64","author":"Schwartz CL","year":"2017","unstructured":"Schwartz CL, Chen L, McCarten K, et al.. Childhood Hodgkin International Prognostic Score (CHIPS) predicts event-free survival in Hodgkin lymphoma: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2017, 64:e26278. 10.1002\/pbc.26278","journal-title":"Pediatr Blood Cancer"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/108392-the-outcome-of-hodgkin-lymphoma-with-reference-to-prognostic-markers","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:49:05Z","timestamp":1707508145000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/108392-the-outcome-of-hodgkin-lymphoma-with-reference-to-prognostic-markers"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,26]]},"references-count":30,"URL":"https:\/\/doi.org\/10.7759\/cureus.28421","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8,26]]}}}